Generalized Anxiety Disorder Clinical Trial
— INTREPIDOfficial title:
The Potential of Virtual Reality as Anxiety Management Tool: a Randomised Controlled Study in a Sample of Patients Affected by Generalized Anxiety Disorder
Verified date | January 2008 |
Source | Istituto Auxologico Italiano |
Contact | n/a |
Is FDA regulated | No |
Health authority | Italy: Ministry of Health |
Study type | Interventional |
Generalized Anxiety Disorder (GAD) is a psychiatric disease characterized by long-lasting
anxiety that is not focused on a specific object or situation. According to the DSM-IV-TR
the essential feature of GAD is at least six months of "excessive anxiety and worry" about a
variety of events and situations. Anxiety and worry are often accompanied by a variety of
physical symptoms like restlessness, being easily fatigued, difficulty concentrating,
irritability, muscle tension and disturbed sleep. The high prevalence of GAD in the general
population and the severe limitations it causes point out the necessity to find new
strategies to treat it in a more efficient way. Within the treatment of GAD, physical
(relaxation and controlled breathing), behavioral (visualization and controlled exposure)
and cognitive control strategies (challenging negative thoughts) represent a key part of the
treatment, even if they are hard to be learned. Given the features of this disease and its
pervasive effect on patient's personal, occupational and affective life, we thought it could
benefit from an ubiquitous treatment.We suggested, then, to improve the treatment of GAD
through the use of a biofeedback enhanced virtual reality (VR) system used for relaxation,
controlled exposure and SIT. The use of SIT in the context of GAD is motivated by the
acknowledgment that sometimes stressors can't be avoided or altered and then patients can't
apply strategies focused on finding solutions. In these instances, coping effort should be
directed to emotionally palliative set of responses such as acceptance, reframing and
perspective thinking. All these cognitive changes are facilitated if a concomitant
relaxation is induced. The treatment involves two virtual reality components:
I) an immersive virtual reality system experienced in the therapist's office;
II) a mobile exposure system allowing patients to perform the virtual experience in an
outpatient setting. The role of the mobile exposure system is the following:
- To present and structure emotionally relevant contents in an ubiquitous context.
- To verify the compliance of the patient and eventually alert patient/therapist;
- To track in real-time the emotional level of the patient and record it for later
assessment by the therapist;
- To provide a feedback to the patient able to help him in coping with the contents;
- To automatically contact the therapist if the emotional level is higher than a preset
cut-off value defined by the therapist.
Status | Completed |
Enrollment | 24 |
Est. completion date | June 2011 |
Est. primary completion date | December 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: 1. Primary diagnosis of GAD 2. Requesting treatment for their GAD 3. Older than 17 and younger than 70; (4) no change in dose of psychotropic medications 1 month before inclusion Exclusion Criteria: 1. Depressive disorder preceding the current episode of GAD or requiring immediate treatment 2. Behavior therapy received for their GAD 3. Evidence of organic mental disorders accounting for the complaints, mental retardation, psychotic disorders, alcohol or drug dependence 4. Migraine, headache, seizure disorder, and vestibular abnormalities since they represent significant contraindications for the use of VR. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Italy | Istituto Auxologico Italiano | Milano |
Lead Sponsor | Collaborator |
---|---|
Istituto Auxologico Italiano |
Italy,
Gorini A, Riva G. The potential of virtual reality as anxiety management tool: a randomized controlled study in a sample of patients affected by generalized anxiety disorder. Trials. 2008 May 5;9:25. doi: 10.1186/1745-6215-9-25. — View Citation
Repetto C, Gorini A, Algeri D, Vigna C, Gaggioli A, Riva G. The use of biofeedback in clinical virtual reality: the intrepid project. Stud Health Technol Inform. 2009;144:128-32. — View Citation
Repetto C, Gorini A, Vigna C, Algeri D, Pallavicini F, Riva G. The use of biofeedback in clinical virtual reality: the INTREPID project. J Vis Exp. 2009 Nov 12;(33). pii: 1554. doi: 10.3791/1554. — View Citation
Riva G, Gorini A, Gaggioli A. The Intrepid project - biosensor-enhanced virtual therapy for the treatment of generalized anxiety disorders. Stud Health Technol Inform. 2009;142:271-6. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | level of anxiety measured by: psychometric questionnaires (PSWQ, BAI, Anti, CID, STAI) and psychophysiological measures ((skin conductance response (SCR), muscle tension, heart and respiratory rates) | immediately before and after each treatment session. At follow up (6 and 12 months) | No | |
Secondary | subjective measures (diary) | during the treatment and during the follow up period | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03420456 -
Transcranial Pulse Near-Infrared Light in Generalized Anxiety Disorder: a Placebo-Controlled Study
|
N/A | |
Active, not recruiting |
NCT05530642 -
An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel
|
N/A | |
Withdrawn |
NCT02382224 -
Worry Exposure for Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT02256566 -
Cognitive Training for Mood and Anxiety Disorders
|
N/A | |
Completed |
NCT02306356 -
Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting
|
N/A | |
Completed |
NCT01958788 -
Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT01681329 -
Cognitive-Behavioral Treatment and Interpretation Modification Training for Adults With Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT01342120 -
PHARMO Institute Seroquel Safety Study
|
N/A | |
Completed |
NCT01201967 -
A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
|
Phase 4 | |
Completed |
NCT01337713 -
Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder (GAD)
|
N/A | |
Completed |
NCT00961298 -
An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder
|
Phase 4 | |
Completed |
NCT01203293 -
Cognitive Behavioral Therapy (CBT) for Latinos With Generalized Anxiety Disorder in the General Medical Sector
|
Phase 1 | |
Completed |
NCT01971203 -
Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat
|
N/A | |
Terminated |
NCT01244711 -
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
|
Phase 4 | |
Completed |
NCT00711737 -
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
|
N/A | |
Completed |
NCT00744627 -
Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.
|
Phase 3 | |
Completed |
NCT00537615 -
An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT00515242 -
Therapeutic Massage for Generalized Anxiety Disorder
|
Phase 1/Phase 2 | |
Completed |
NCT00525226 -
Evaluating the Effects of Stress in Pregnancy
|
N/A | |
Completed |
NCT00368745 -
Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.
|
Phase 3 |